Kristel Kemper, Ph.D.

Director, Translational Research at Genmab

Speaker

Kristel Kemper earned her PhD in 2012 from the University of Amsterdam, the Netherlands, with her thesis titled "Molecular Identification and Targeting of Colorectal Cancer Stem Cells." During her postdoctoral research at the Netherlands Cancer Institute in Amsterdam, she explored resistance mechanisms to the BRAF inhibitor vemurafenib using melanoma patient-derived xenografts.

In 2017, Dr. Kemper joined Genmab as a Scientist, where she was responsible for the development of therapeutic antibodies with an emphasis on oncology. She now serves as the team lead for the Translational Research Group at Genmab. In this capacity, she oversees the design and implementation of translational strategies for novel antibody compounds in preclinical and early clinical development, including the formulation of biomarker strategies for first-in-human trials.